Ampio Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company headquartered in Greenwood Village, Colorado. The company is focused on the development and commercialization of novel therapies for inflammatory conditions and unmet medical needs. Ampio’s development programs center on biologic and small‐molecule candidates designed to modulate inflammatory and immunologic pathways, with an emphasis on treatments that can be administered in outpatient and acute care settings.
Ampio’s lead product candidate, Ampion, is a proprietary, single‐agent formulation derived from human serum albumin and enriched with immunomodulatory proteins. It is being evaluated primarily for the treatment of osteoarthritis pain in the knee, where recent clinical trials have assessed its potential to reduce pain and improve joint function. In parallel, the company is advancing additional pipeline assets for traumatic brain injury and other inflammatory disorders, utilizing a targeted approach to address both symptom relief and underlying disease progression.
Originally incorporated in 2010, Ampio has evolved from an early‐stage research organization into a publicly traded entity listed on the New York Stock Exchange under the symbol AMPE. Over the years, the company has forged partnerships with regional contract research organizations to conduct multi‐center clinical studies and has engaged regulatory consultants to navigate the U.S. Food and Drug Administration and other global regulatory pathways.
Ampio serves patients and healthcare providers across North America and is actively exploring opportunities for international collaborations. Its executive leadership team comprises industry veterans with extensive backgrounds in biologics, drug development, regulatory affairs and commercial strategy. Through a combination of targeted research programs and strategic partnerships, Ampio aims to bring new, science‐driven treatments to market for patients suffering from chronic inflammatory conditions.
AI Generated. May Contain Errors.
